Literature DB >> 21696733

Impact of pH on the antifungal susceptibility of vaginal Candida albicans.

Wei Liu1, Xu Zhang, Zhaohui Liu, Xin Luo.   

Abstract

OBJECTIVE: To investigate the antifungal susceptibility at pH 7.0 and pH 4.0 of 5 antifungal agents against Candida albicans isolated from patients with vulvovaginal candidiasis.
METHODS: Antifungal susceptibility testing at pH 7.0 and pH 4.0 was performed using the broth microdilution method (CLSI, document M27-A2).
RESULTS: The minimal inhibitory concentrations (MICs) of miconazole, clotrimazole, fluconazole, and nystatin against C. albicans at pH 4.0 were significantly higher than those at pH 7.0 (0.25 vs 0.03 μg/mL, 0.50 vs 0.03 μg/mL, 0.50 vs 0.25 μg/mL, and 32 vs 2 μg/mL, respectively; P<0.001), whereas the MIC of itraconazole at pH 4.0 was lower than that at pH 7.0 (0.030 vs 0.125 μg/mL; P<0.001). The susceptibility rate of C. albicans to itraconazole at pH 4.0 was significantly higher than at pH 7.0 (95.0% vs 51.7%; P<0.001). The susceptibility rate to itraconazole at pH 7.0 was significantly lower than the susceptibility rate to fluconazole (51.7% vs 100.0%; P<0.001), whereas the susceptibility rates to the 2 drugs were similar at pH 4.0 (95.0% and 96.7%, respectively).
CONCLUSION: Media at different pH values should be used for sensitivity tests according to the environment of C. albicans. Crown
Copyright © 2011. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696733     DOI: 10.1016/j.ijgo.2011.03.016

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  9 in total

Review 1.  Factors influencing susceptibility testing of antifungal drugs: a critical review of document M27-A4 from the Clinical and Laboratory Standards Institute (CLSI).

Authors:  Edinaira Sulany Oliveira de Sousa; Ana Claúdia Alves Cortez; Marcia de Souza Carvalho Melhem; Hagen Frickmann; João Vicente Braga de Souza
Journal:  Braz J Microbiol       Date:  2020-08-05       Impact factor: 2.476

2.  Determining Susceptibility in Candida Vaginal Isolates.

Authors:  Jack D Sobel; Robert Akins
Journal:  Antimicrob Agents Chemother       Date:  2022-05-23       Impact factor: 5.938

3.  Mechanism of action of efinaconazole, a novel triazole antifungal agent.

Authors:  Yoshiyuki Tatsumi; Maria Nagashima; Toshiyuki Shibanushi; Atsushi Iwata; Yumi Kangawa; Fumie Inui; William J Jo Siu; Radhakrishnan Pillai; Yayoi Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

4.  Vulvovaginal candidiasis and current perspectives: new risk factors and laboratory diagnosis by using MALDI TOF for identifying species in primary infection and recurrence.

Authors:  Lívia Custódio Pereira; Amabel Fernandes Correia; Zita Dinis Lopes da Silva; Ceres Nunes de Resende; Fabiana Brandão; Rosane Mansan Almeida; Yanna Karla de Medeiros Nóbrega
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-13       Impact factor: 3.267

5.  Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.

Authors:  Sujit D Rathod; Patricia A Buffler
Journal:  BMC Womens Health       Date:  2014-03-10       Impact factor: 2.809

6.  In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.

Authors:  Dina A Boikov; Jeffrey B Locke; Kenneth D James; Ken Bartizal; Jack D Sobel
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

7.  Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.

Authors:  Jeffrey B Locke; Amanda L Almaguer; Joanna L Donatelli; Ken F Bartizal
Journal:  Infect Dis Obstet Gynecol       Date:  2018-02-22

8.  A buffered media system for yeast batch culture growth.

Authors:  Rianne C Prins; Sonja Billerbeck
Journal:  BMC Microbiol       Date:  2021-04-23       Impact factor: 3.605

9.  In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis.

Authors:  Jack D Sobel; Katyna Borroto-Esoda; Nkechi Azie; David Angulo
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.